Debate of the Decade: RCTs in the Era of Precision Oncology
How do you design clinical trials in the era of precision oncology? Are prospective randomized controlled trials necessary anymore? Drs. Ray Kurzrock, Vivek Subbiah, and Christopher Booth join Dr. Chadi Nabhan to answer these important questions.
Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations
How Has COVID-19 Reshaped the World of Drug Discovery?
Evaluating HER2-Low in Metastatic Breast Cancer: Cytological Insights Into Proliferation and Survival